Literature DB >> 27255742

Reimbursable drug classes and ceilings in Italy: why not only one?

Livio Garattini1, Alessandro Curto2, Anna Padula2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27255742     DOI： 10.1007/s10198-016-0808-z

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  7 in total

1.  Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?

Authors:  Livio Garattini; Alessandro Curto; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

2.  Off-patent drugs in Italy. A short-sighted view?

Authors:  Livio Garattini; Simone Ghislandi
Journal:  Eur J Health Econ       Date:  2006-03

3.  Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries.

Authors:  Livio Garattini; Nicola Motterlini; Dante Cornago
Journal:  Health Policy       Date:  2007-10-10       Impact factor: 2.980

4.  Regional HTA in Italy: promising or confusing?

Authors:  Livio Garattini; Katelijne van de Vooren; Alessandro Curto
Journal:  Health Policy       Date:  2012-11-09       Impact factor: 2.980

5.  Italian risk-sharing agreements on drugs: are they worthwhile?

Authors:  Livio Garattini; Alessandro Curto; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2015-01

6.  'Appropriateness' in Italy: A 'Magic Word' in Pharmaceuticals?

Authors:  Livio Garattini; Anna Padula
Journal:  Appl Health Econ Health Policy       Date:  2017-02       Impact factor: 2.561

7.  The puzzle of drug delivery in Italy: who wins?

Authors:  Livio Garattini; Alessandro Curto; Anna Padula
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2016-05-03       Impact factor: 2.217
  7 in total
  3 in total

1.  Pharmaceutical pricing conundrum: time to get rid of it?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-11

2.  Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.

Authors:  Marina Morgado Garcia; Pamela Santos Azevedo; Andrew Mirelman; Leandro Pinheiro Safatle; Roberto Iunes; Marion Clark Bennie; Brian Godman; Augusto Afonso Guerra Junior
Journal:  Front Pharmacol       Date:  2020-04-14       Impact factor: 5.810

3.  Community and hospital pharmacists in Europe: encroaching on medicine?

Authors:  Livio Garattini; Anna Padula; Pier Mannuccio Mannucci
Journal:  Intern Emerg Med       Date:  2020-09-13       Impact factor: 3.397
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.